Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs
نویسندگان
چکیده
منابع مشابه
Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
OBJECTIVE This article's objective is to critically assess the Bulgarian legislation on health technology assessment (HTA). It analyses how innovative therapies and orphan drugs in particular would respond to the regulators' decision-making criteria for reimbursement. MATERIALS AND METHODS The study features critical analysis of current decision-making criteria for drug reimbursement in Bulga...
متن کاملCriteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria.
BACKGROUND During times of fiscal austerity, means of reimbursement decision-making are of particular interest for public health theory and practice. Introduction of advanced health technologies, growing health expenditures and increased public scrutiny over drug reimbursement decisions have pushed governments to consider mechanisms that promote the use of effective health technologies, while c...
متن کاملMarket access of orphan drugs and the role of multi-criteria decision making
Background A number of factors play a role in market access of orphan drugs, such as the extent to which an orphan drug meets a medical need; existence of alternative health technologies; disease prevalence; number of orphan drug indications; and added clinical benefit of the orphan drug. How can these factors be taken into account in market access decisions given that there is uncertainty over...
متن کاملValue-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
BACKGROUND The rate of development of new orphan drugs continues to grow. As a result, reimbursing orphan drugs on an exceptional basis is increasingly difficult to sustain from a health system perspective. An understanding of the value that societies attach to providing orphan drugs at the expense of other health technologies is now recognised as an important input to policy debates. OBJECTI...
متن کاملReimbursement of orphan drugs in Belgium: what (else) matters?
BACKGROUND Most orphan drugs do not meet traditional standards of cost-effectiveness. Yet, most orphan drugs are reimbursed, which implies that other factors are taken into account at the time of reimbursement. To increase accountability of decision-makers, there is a need for more transparency in the factors that play a role in reimbursement decisions of orphan drugs. Therefore, the aim of thi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Folia Medica
سال: 2013
ISSN: 1314-2143,0204-8043
DOI: 10.2478/folmed-2013-0032